Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective

References

• International Agency for Research on Cancer (IARC). Brazil fact sheets. GLOBOCAN 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/76-brazil-fact-sheets.pdf.
   Google Scholar
• An estimate of premature deaths averted with immunotherapy in treating Brazilian patients with advanced clear cell renal cell carcinoma. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e16114#:∼:text=Background%3A%20Clear%20cell%20renal%20cell,in%20metastatic%20RCC%20(mRCC).
   Google Scholar
• Aguiar P, Jr., Padua TC, Guimaraes DP. Brazilian data of renal cell carcinoma in a public university hospital. Int Braz J Urol. 2016;42(1):29–36. doi: 10.1590/S1677-5538.IBJU.2014.0452.
   PubMed Web of Science ®Google Scholar
• Engel Ayer Botrel T, Datz Abadi M, Chabrol Haas L, et al. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. J Med Econ. 2021;24(1):291–298. doi: 10.1080/13696998.2021.1883034.
   PubMed Web of Science ®Google Scholar
• Oliveira AP, Roubik C, Dyer M, et al. Immunotherapy-based first-line treatment of intermediate-and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system. JBES. 2021;13(3):258–267. doi: 10.21115/JBES.v13.n3.p258-67.
   Google Scholar
• Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res. 1999;19(2C):1541–1543.
   PubMed Web of Science ®Google Scholar
• Calvo E, Porta C, Grünwald V, et al. The current and evolving landscape of first-line treatments for advanced renal cell carcinoma. Oncologist. 2019;24(3):338–348. doi: 10.1634/theoncologist.2018-0267.
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799. doi: 10.1200/JCO.2008.21.4809.
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–148. doi: 10.1016/S1470-2045(12)70559-4.
   PubMed Web of Science ®Google Scholar
• Bergerot PG, Bergerot CD, Dizman N, et al. Assessment of treatment patterns for metastatic renal cell carcinoma in Brazil. J Glob Oncol. 2018;4:1–8. doi: 10.1200/JGO.17.00113.
   PubMed Web of Science ®Google Scholar
• Smaletz O, Dias M, Mata J, et al. Diretrizes de tratamentos oncológicos recomendados pela Sociedade Brasileira de Oncologia Clínica – Rim. Diretrizes 2022 – Atualização. 2022.; Available from: https://www.sboc.org.br/images/16.-Diretrizes-SBOC-2022---Rim-v5-FINAL.pdf.
   Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced Renal-Cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi: 10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced Renal-Cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi: 10.1056/NEJMoa1816714.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022;128(11):2085–2097. doi: 10.1002/cncr.34180.
   PubMed Web of Science ®Google Scholar
• Rini BI. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. 2021;4500–4500.
   Google Scholar
• Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563–1573. doi: 10.1016/S1470-2045(20)30436-8.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32(5):667–677. doi: 10.1177/0272989X12454577.
   PubMed Web of Science ®Google Scholar
• Brasil Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: diretriz de Avaliação Econômica/Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insu mos Estratégicos, Departamento de Ciência e Tecnologia. – 2. ed. – Brasília: Ministério da Saúde, 2014. Available from: https://www.gov.br/conitec/pt-br/midias/artigos_publicacoes/diretrizes/diretrizes_metodologicas_diretriz_avaliacao_economica.pdf.
   Google Scholar
• Nardi AC, Zequi SdC, Clark OAC, et al. Epidemiologic characteristics of renal cell carcinoma in Brazil. Int Braz J Urol. 2010;36(2):151–157; discussion 158. discussion 158. doi: 10.1590/s1677-55382010000200004.
   PubMed Web of Science ®Google Scholar
• Brazilian Institute of Geography and Statistics. Tábua completa de mortalidade para o Brasil. Rio de Janeiro, 2020. Disponível em Available from: https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&id=73097.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). TA780: nivolumab with ipilimumab for untreated advanced renal cell carcinoma: final appraisal document. 2022. Available from: https://www.nice.org.uk/guidance/ta780/evidence.
   Google Scholar
• Cope S, Chan K, Campbell H, et al. A comparison of alternative network meta-analysis methods in the presence of nonproportional hazards: a case study in first-line advanced or metastatic renal cell carcinoma. Value Health. 2023;26(4):465–476. doi: 10.1016/j.jval.2022.11.017.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for Population-Adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211. doi: 10.1177/0272989X17725740.
   PubMed Web of Science ®Google Scholar
• Rohatgi A. WebPlotDigitizer. 2017; Available from: http://arohatgi.info/WebPlotDigitizer/index.html.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi: 10.1186/1471-2288-12-9.
   PubMed Web of Science ®Google Scholar
• Saluja R, Cheng S, Delos Santos KA, et al. Estimating hazard ratios from published Kaplan-Meier survival curves: a methods validation study. Res Synth Methods. 2019;10(3):465–475. doi: 10.1002/jrsm.1362.
   PubMed Web of Science ®Google Scholar
• Applied survival analysis: regression modeling of time-to-Event data., 2nd edition by HOSMER, D. W., LEMESHOW, S., and MAY, S. Biometrics, 2009. 65(2): p. 671–672.
   Google Scholar
• R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2022. Available from: https://www.R-project.org/.
   Google Scholar
• Wang., et al. 2019. Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/metastatic renal cell carcinoma.
   Google Scholar
• Bensimon AG, Zhong Y, Swami U, et al. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. Curr Med Res Opin. 2020;36(9):1507–1517. doi: 10.1080/03007995.2020.1799771.
   PubMed Web of Science ®Google Scholar
• NICE. Single Technology Appraisal Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426] Committee papers. 2019.
   Google Scholar
• Viegas Andrade M, Noronha K, Kind P, et al. Societal preferences for EQ-5D health states from a Brazilian population survey. Value Health Reg Issues. 2013;2(3):405–412. doi: 10.1016/j.vhri.2013.01.009.
   PubMedGoogle Scholar
• EMA. Assessment report Keytruda, in Assessment report. 2015, European Medicines Agency
   Google Scholar
• Bedke J, Rini BI, Plimack ER. Health-related quality-of-life analysis from KEYNOTE-426: pembrolizumab + axitinib vs sunitinib for advanced renal cell carcinoma, in. Eau 2020 Qol. 2020;
   Google Scholar
• Bedke J, Rini BI, Plimack ER, et al. Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. Eur Urol. 2022;82(4):427–439. doi: 10.1016/j.eururo.2022.06.009.
   PubMed Web of Science ®Google Scholar
• Agência Nacional de Vigilância Sanitária - Anvisa. Listas de preços de medicamentos. 2022. Available from: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/cmed/precos.
   Google Scholar
• Watson TR, Gao X, Reynolds KL, et al. Cost-effectiveness of pembrolizumab plus axitinib Vs nivolumab plus ipilimumab as First-Line treatment of advanced renal cell carcinoma in the US. JAMA Netw Open. 2020;3(10):e2016144. doi: 10.1001/jamanetworkopen.2020.16144.
   PubMed Web of Science ®Google Scholar
• Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214). Available from: https://clinicaltrials.gov/ct2/show/NCT02231749.
   Google Scholar
• Classificação Brasileira Hierarquizada de Procedimentos Médicos (CBHPM). 2012. Disponível em. Available from: https://sbacvsp.com.br/Procedimentos/Tabela-CBHPM-Geral.pdf.
   Google Scholar
• Plimack ER, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): updated analysis of KEYNOTE-426. 2020, American Society of Clinical Oncology.
   Google Scholar
• CONVÊNIO ICMS 162/94—Conselho Nacional de Política Fazendária CONFAZ. 2023; Available from: https://www.confaz.fazenda.gov.br/legislacao/convenios/1994/CV162_94.
   Google Scholar
• NICE. Single Technology Appraisal Cabozantinib for untreated advanced renal cell carcinoma [ID1208] Committee papers. 2018.
   Google Scholar
• Shay R, Nicklawsky A, Gao D, et al. A Cost-Effectiveness analysis of nivolumab plus ipilimumab versus pembrolizumab plus axitinib and versus avelumab plus axitinib in First-Line treatment of advanced renal cell carcinoma. Clin Genitourin Cancer. 2021;19(4):370–370 e7. doi: 10.1016/j.clgc.2021.01.009.
   PubMed Web of Science ®Google Scholar
• Zarrabi KK, Handorf E, Miron B, et al. Comparative effectiveness of Front-Line ipilimumab and nivolumab or axitinib and pembrolizumab in metastatic clear cell renal cell carcinoma. Oncologist. 2023;28(2):157–164. doi: 10.1093/oncolo/oyac195.
   PubMed Web of Science ®Google Scholar
• Leonart Garmatter L, Rego BF, Bastos DA, et al. Cost-Effectiveness of Pembrolizumab + Axitinib Versus Nivolumab + Ipilimumab As First-Line Treatment of Advanced Renal Cell Carcinoma in the Private Healthcare System in Brazil. 2023 [cited 2023; Available from: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2023-3669/126054.
   Google Scholar
• Riaz IB, He H, Ryu AJ, et al. A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma. Eur Urol. 2021;80(6):712–723. doi: 10.1016/j.eururo.2021.03.016.
   PubMed Web of Science ®Google Scholar
• Regan M. Treatment-free survival, with and without toxicity, after immuno-oncology versus targeted therapy for advanced renal cell carcinoma: 42-month results of CheckMate 214. Poster presentation at the European Society for Medical Oncology (ESMO) Congress; September 19- 21, 2020. Virtual Meeting. 2020
   Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. 661P conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab + ipilimumab (N + I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Annals of Oncology. 2021;32: s 685–S687. doi: 10.1016/j.annonc.2021.08.057.
   Web of Science ®Google Scholar